This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
by Ekta Bagri
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
INSMNegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
by Zacks Equity Research
Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.
RVMDPositive Net Change BMYPositive Net Change SMMTPositive Net Change TNGXNegative Net Change
biotechs medical pharmaceuticals
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
by Ekta Bagri
BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.
BMYPositive Net Change CYTKPositive Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
by Aparajita Dutta
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
NVSPositive Net Change BIIBNegative Net Change RHHBYNegative Net Change LLYPositive Net Change ABBVPositive Net Change XLVPositive Net Change PPHPositive Net Change IXJPositive Net Change IBRNNegative Net Change
biotechs etfs medical pharmaceuticals
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
by Zacks Equity Research
Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
BHVNPositive Net Change ACIUPositive Net Change AMRXPositive Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs?
by Ahan Chakraborty
LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipeline assets add growth opportunities.
LLYPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
HALOPositive Net Change RGENNegative Net Change IOVAPositive Net Change PGENNegative Net Change ARQTNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
by Ahan Chakraborty
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
NVONegative Net Change GPCRPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
by Sundeep Ganoria
BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
BBIONegative Net Change ALNYPositive Net Change PFEPositive Net Change
biotechs medical
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
by Sundeep Ganoria
BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.
BBIONegative Net Change ALNYPositive Net Change PFEPositive Net Change
biotechs medical